Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study
ConclusionsSerum CLP level was correlated with disease activity in PsA. It also possessed the ability to predict the achievement of the therapeutic target. These features of CLP would make it a useful tool in clinical work. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 21, 2022 Category: Rheumatology Source Type: research
Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center
ConclusionConsiderable discrepancies in MS and CVD were observed between patients with PsA and those with RA. The greater odds of MS and CVD emphasize the need to pay more attention to metabolic and cardiovascular conditions in patients with PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 20, 2022 Category: Rheumatology Source Type: research
Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
ConclusionsThis was the first real-world, non-interventional study to report systematically collected radiographic data in a large cohort of patients with RA or PsA under treatment with a biologic. In patients with available radiographic data, mean radiographic progression was lower and the proportion of patients without progression was greater during ETN treatment than in the pre-ETN period. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 17, 2022 Category: Rheumatology Source Type: research
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
ConclusionsIn PsA patients, efficacy responses were similar or greater with UPA15 or UPA30 versus ADA through week 104, and inhibition of radiographic progression was maintained. No new safety risks were identified with exposure to UPA through 2 years (week 104).Clinical Trial RegistrationClinicalTrials.gov, NCT03104400. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 15, 2022 Category: Rheumatology Source Type: research
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
ConclusionIn real-world settings, patients with RA initiating treatment with baricitinib were older and had longer disease duration than those initiating treatment with any other tsDMARD or any bDMARD. Initial descriptive data regarding treatment discontinuation (including reasons for discontinuation), effectiveness, and treatment patterns will be enriched as the study progresses. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 13, 2022 Category: Rheumatology Source Type: research
Validation of the PROFAD-SSI-SF in Patients with Primary Sj ögren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses
ConclusionThe final disease model confirmed that the PROFAD-SSI-SF assesses concepts that are relevant and important to patients with pSS. Our findings support the content validity and measurement properties of the PROFAD-SSI-SF as a fit-for-purpose PRO measure appropriate for use in clinical trials in patients with pSS.Clinical Trial Registration number for the phase 2 trialClinicaltrials.gov NCT02631538 (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 13, 2022 Category: Rheumatology Source Type: research
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
ConclusionsIn high-risk (four PPFs) patients with MTX-IR RA, FIL200 and FIL100 showed similar reductions in disease activity versus placebo at W12 as in patients with fewer than four PPFs. mTSS in patients receiving FIL200 changed little from W24 to W52, while that in patients receiving FIL100 progressed comparably to patients who received adalimumab. Tolerability was comparable across treatment arms and subgroups. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 9, 2022 Category: Rheumatology Source Type: research
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
ConclusionFilgotinib efficacy and safety in patients with RA were generally consistent across geographic regions.ClinicalTrials.gov Trial Registration NumbersNCT02889796; NCT02873936; NCT02886728; NCT03025308; NCT01888874; NCT01894516; NCT02065700.Graphical Abstract (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 7, 2022 Category: Rheumatology Source Type: research
Population Pharmacokinetics and Exposure –Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
ConclusionsRisankizumab exhibited linear and time-independent pharmacokinetics in patients with PsA and was comparable to patients with plaque psoriasis. Efficacy and safety exposure –response analyses support that the clinical regimen achieved robust efficacy with a favorable safety profile for patients with active PsA.Clinical Trials: NCT02596217, NCT02719171, NCT02986373, NCT03671148, and NCT03675308.Clinical Trials: NCT02596217, NCT02719171, NCT02986373, NCT03671148, and NCT03675308. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 30, 2022 Category: Rheumatology Source Type: research
Long-Term Adherence to Etanercept in Treatment Effectiveness of Patients with Spondyloarthritis: 7-Year Data from the Iraq National Registry
ConclusionsThese results suggest that Iraqi patients with SpA benefit from long-term adherence to etanercept treatment; however, additional analyses are needed to further assess the reasons for treatment discontinuation, which may include disease remission.Trial RegistrationClinicalTrials.gov: NCT04507776. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 30, 2022 Category: Rheumatology Source Type: research
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
ConclusionCZP was effective in reducing AAU incidence in clinical trials with patients with axSpA. The targeted literature review, however, highlighted that there remains a paucity of data beyond these trials. Data from comparative studies would further enhance the body of evidence on the effects of CZP in patients with axSpA who develop AAU.Graphical abstract (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 30, 2022 Category: Rheumatology Source Type: research
Combination of Enzymes and Rutin to Manage Osteoarthritis Symptoms: Lessons from a Narrative Review of the Literature
AbstractOsteoarthritis is the most common joint disorder affecting over 300 million people worldwide. It typically affects the knees and the hips, and is characterized by a loss in normal joint movement, stiffness, swelling, and pain in patients. The current gold standard therapy for osteoarthritis targets pain management using nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are associated with several potentially serious side effects, the most common being gastrointestinal perforation and bleeding. Owing to the side effects, NSAID treatment doses need to be as low as possible and should be continued for the shortest...
Source: Rheumatology and Therapy - September 26, 2022 Category: Rheumatology Source Type: research
Content Validity of Sj ögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s
ConclusionsSSSD and FACIT-F are content valid in a Sj ögren’s population, meeting an important criterion to support their use as clinical trial endpoints, but also their use in clinical practice and other research settings. Qualitative data exploring meaningful change will be valuable in supporting psychometrically derived responder definitions. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 24, 2022 Category: Rheumatology Source Type: research
Reproductive Healthcare in Women with Rheumatoid Arthritis and Psoriatic Diseases in Routine Clinical Practice: Survey Results of Rheumatologists and Dermatologists
ConclusionsThere is a need for more holistic, multidisciplinary, collaborative, and integrated communication between clinicians and women of childbearing age. Physicians should consider the implications of these conditions and medical treatment for women of childbearing age and family planning for those with rheumatoid arthritis and psoriatic disease. Patient-centered care that includes patients ’ reproductive choices should be a routine clinical practice. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 24, 2022 Category: Rheumatology Source Type: research
Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
ConclusionsThese real-world findings provide further support for increased pegloticase response rates when co-treatment with immunomodulating therapy is used. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 22, 2022 Category: Rheumatology Source Type: research
